April 25, 2014 5:55 AM ET

Pharmaceuticals

Company Overview of Par Pharmaceutical Companies Inc.

Company Overview

Par Pharmaceutical Companies, Inc. is engaged in developing, licensing, manufacturing, marketing, and distributing generic and branded drugs in the United States. It operates in two segments, Generic Pharmaceuticals and Branded Pharmaceuticals. The Generic Pharmaceuticals segment markets authorized generics, including metformin ER, glyburide and metformin HCl, fluticasone, and ranitidine HCl syrup, as well as metoprolol succinate ER, budesonide, and rizatriptan. This segment also markets pharmaceutical products, including Lamictal XR, Luvox CR, Focalin XR, RythmolSR, and Provigil. This segment serves wholesalers, drug store chains, supermarket chains, mass merchandisers, distributors, mail o...

300 Tice Boulevard

Woodcliff Lake, NJ 07677

United States

Founded in 1978

978 Employees

Phone:

201-802-4000

Key Executives for Par Pharmaceutical Companies Inc.

Chief Executive Officer
Age: 51
Chief Financial Officer
Age: 55
Chief Operating Officer
Chief Commercial Officer
Age: 56
Secretary and Deputy General Counsel
Compensation as of Fiscal Year 2013.

Par Pharmaceutical Companies Inc. Key Developments

Par Pharmaceutical Appoints Terrance Coughlin as New COO

Par Pharmaceutical Companies Inc. has appointed Terrance Coughlin as its new COO. In this capacity, Mr. Coughlin will be responsible for Par's global manufacturing activities, R&D efforts and will be instrumental in the new product selection process. Mr. Coughlin joins Par from Glenmark Generics Inc. USA/Glenmark Generics Limited where he most recently served as president and CEO for more than six years. Prior to that position, he served as president, Glenmark Generics Inc., USA.

Par Pharmaceutical Companies Inc. Names Terrance J. Coughlin as Chief Operating Officer

Par Pharmaceutical Companies Inc. announced that Terrance J. Coughlin has been named chief operating officer. In this capacity, Coughlin will be responsible for Par's global manufacturing activities, research and development efforts and will be instrumental in the new product selection process. Coughlin joins Par from Glenmark Generics Inc. USA/Glenmark Generics Limited where he most recently served as president and chief executive officer for more than six years. Prior to that position, he served as president, Glenmark Generics Inc., USA.

Par Pharmaceutical Companies Inc., Q4 2013 Earnings Call, Mar 20, 2014

Par Pharmaceutical Companies Inc., Q4 2013 Earnings Call, Mar 20, 2014

Similar Private Companies By Industry

Company Name Region
Ventaira Pharmaceuticals, Inc. United States
Putney, Inc. United States
Marc Pharmaceuticals, Inc. United States
LAM Therapeutics Inc. United States
IBC Pharmaceuticals, L.L.C. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
January 21, 2014
JHP Pharmaceuticals, LLC
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Par Pharmaceutical Companies Inc., please visit www.parpharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.